MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cidara Therapeutics Company Profile (NASDAQ:CDTX)

Consensus Ratings for Cidara Therapeutics (NASDAQ:CDTX) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $18.33 (76.79% upside)

Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)
Show:
DateFirmActionRatingPrice TargetActions
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016WedbushReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2015Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/9/2015WBB SecuritiesUpgradeSell -> Hold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015BTIG ResearchInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Cidara Therapeutics (NASDAQ:CDTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.82)($0.75)($0.78)
Q2 20163($0.85)($0.77)($0.80)
Q3 20163($0.90)($0.78)($0.83)
Q4 20163($0.95)($0.79)($0.86)
(Data provided by Zacks Investment Research)
Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cidara Therapeutics (NASDAQ:CDTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cidara Therapeutics (NASDAQ:CDTX)
DateHeadline
06/24/16 03:06 PMCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 03:16 PMThe Market Is Ignoring The Potential Of Scynexis' SCY-098 In Invasive Fungal Infections
06/22/16 07:51 AMpSivida (PSDV), The ONE (STKS), Trinity Place (TPHS), Cidara (CDTX) Post Gaps Up today
06/10/16 03:11 PMCidara Therapeutics (CDTX) Doses First Patient in Phase 2 Trial of CD101 Topical to Treat VVC
06/09/16 06:39 AMCidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis - [at noodls] - SAN DIEGO--(BUSINESS WIRE)--Jun. 9, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today ...
06/08/16 06:48 AMCidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 - [at noodls] - Results from Multiple Dose Phase 1 Trial of CD101 IV Supporting High-Exposure, Once-Weekly Dosing Will Be Presented For the First Time SAN DIEGO--(BUSINESS WIRE)--Jun. 8, 2016-- Cidara Therapeutics, Inc. ...
06/06/16 01:31 PMCidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/02/16 11:54 AMCDTX: Insiders vs. Shorts - In the case of Cidara Therapeutics Inc (CDTX), the total short interest at the 03/31/2016 settlement date was 428,357 shares, which compares to the average daily trading volume of just 40,175 shares, for a "days to cover" ratio of 10.66. When short sellers ...
06/02/16 07:15 AMCidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - SAN DIEGO, June 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, ...
06/01/16 09:15 PMCidara Therapeutics (CDTX) Granted FDA Fast Track Status for CD101 Topical - Join here. Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced that the U.S. Food and Drug Administration (FDA) has designated the company’s novel antifungal product candidate, CD101 topical, as a Qualified Infectious Disease Product (QIDP), with Fast ...
05/31/16 06:52 AMFDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate - [at noodls] - -CD101 Topical designated for treatment of VVC and for prevention of recurrent VVC- SAN DIEGO--(BUSINESS WIRE)--May 31, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing ...
05/20/16 12:04 PMCIDARA THERAPEUTICS, INC. Financials -
05/20/16 05:05 AMCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex -
05/12/16 04:27 PMCidara Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today ...
04/06/16 06:19 AMCidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016 - [at noodls] - Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing SAN DIEGO--(BUSINESS WIRE)--Apr. 6, 2016-- Cidara ...
04/05/16 07:00 AMCidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference - [at noodls] - SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, ...
03/18/16 06:43 AMCidara Therapeutics reports 4Q loss -
03/18/16 06:30 AMCidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - SAN DIEGO, March 18, 2016-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results ...
03/07/16 12:22 PMA Potential Answer To Antibiotic Resistance - [Accesswire] - NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients ...
02/25/16 01:38 PMAnalysts Forecast 35% Upside For VTWG - Three of VTWG's underlying holdings with notable upside to their analyst target prices are Cidara Therapeutics Inc (CDTX), ARC Document Solutions, Inc. (ARC), and CPI Card Group Inc (PMTS). Although CDTX has traded at a recent price of $10.21/share ...
02/18/16 01:20 PMCidara Therapeutics : Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis - IN CANDIDEMIA AND INVASIVE CANDIDIASIS Orphan designation follows QIDP and Fast Track status for CD101 IV Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other ...
02/11/16 01:23 PMCIDARA RECEIVES ORPHAN DRUG DESIGNATION FOR NOVEL ECHINOCANDIN, CD101 IV, IN CANDIDEMIA AND INVASIVE CANDIDIASIS - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...
02/10/16 12:57 PMCidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...
02/10/16 06:40 AMCORRECTING and REPLACING Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis - [Business Wire] - Headline of release should read: Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (instead of Cidara Receives Orphan
02/10/16 06:01 AM7:01 am Cidara Therapeutics confirms that the FDA has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis -
02/03/16 06:30 AMCidara Therapeutics Announces Participation in Leerink Partners 5th Annual Global Healthcare Conference - [GlobeNewswire] - SAN DIEGO, Feb. 03, 2016-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating ...
01/11/16 08:18 AMCidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV - [at noodls] - -- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability - --(BUSINESS WIRE)--Jan. 11, 2016-- (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies ...
12/21/15 08:26 AMCidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines - [at noodls] - New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients --(BUSINESS WIRE)--Dec. 21, 2015-- (Nasdaq:CDTX), a biotechnology company developing novel ...
12/07/15 12:44 PMShould You Avoid Mattson Technology, Inc. (MTSN)? -
12/07/15 06:50 AMWhat's the Market Data Pointing At - Research on Cidara, Alpha and Omega, Park City Group and CRA International - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cidara Therapeutics ...
11/29/15 05:14 PMCidara Therapeutics Inc (CDTX): Are Hedge Funds Right About This Stock? -
11/27/15 07:40 AMNew Information Reveals Opportunity in Volatility - Research on Cidara Therapeutics, Alpha and Omega Semiconductor, Park City Group and CRA International - [Accesswire] - N EW Y ORK , NY / ACCESSWIRE / November 27, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cidara ...
11/16/15 03:34 PMCidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results - [at noodls] - -- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET -- SAN ...
11/16/15 03:02 PMCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
11/16/15 07:00 AMCidara Therapeutics Inc Earnings Call scheduled for 8:00 am ET today -
11/10/15 06:56 AMCidara Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference in London - [at noodls] - SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, ...
About Cidara Therapeutics

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a biotechnology company. The Company is focused on the discovery, development and commercialization of anti-infective products. The Company's products are the formulations of its compound, CD101, which is an echinocandin. Its products include CD101 intravenous (biafungin) and CD101 topical (topifungin). In addition, it owns an immunotherapy technology platform, Cloudbreak. The Company is also developing other candidates for the treatment of bacterial and viral infections. CD101 IV and CD101 topical are in early stage of preclinical development. The Company's Cloudbreak development candidates includeC001 and C016. It has conducted preclinical studies to evaluate the tolerability, toxicity and pharmacokinetic profile of C001 in mice and guinea pigs. Cloudbreak development candidates have demonstrated preclinical proof-of-principle efficacy and safety in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CDTX
  • CUSIP:
Key Metrics:
  • Previous Close: $10.37
  • 50 Day Moving Average: $11.06
  • 200 Day Moving Average: $12.33
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $143.67M
  • Current Quarter EPS Consensus Estimate: $-3.11 EPS
Additional Links:
Cidara Therapeutics (NASDAQ:CDTX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha